Logo

Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Share this

Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Shots:

  • The company has completed the enrolment in the P-III APOLLO-B study to evaluate the efficacy & safety of patisiran vs PBO in a ratio (2:1) in 300 patients with ATTR amyloidosis with cardiomyopathy across 90 sites in 20+ countries. The results are expected in mid-2022
  • The 1EPs of the trial is the change from baseline in 6 min. walk test @12 mos. The 2EPs is to assess the efficacy on health-related QoL- mortality & cardiovascular events- cardiac biomarkers & manifestations of cardiac amyloid
  • Onpattro (Patisiran) is an RNAi therapeutic- approved in US- Canada & Japan for polyneuropathy of hATTR amyloidosis & in EU- Switzerland & Brazil for hATTR amyloidosis with Stage 1 or Stage 2 polyneuropathy

  Ref: Businesswire | Image: Pharmaphorum

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions